MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

NCT01437657 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

319

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Placebo
DRUG: RO4917523 0.5 mg
DRUG: RO4917523 1.5 mg

Sponsor

Hoffmann-La Roche